News from spinifex pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

29 Jun, 2015, 06:00 BST Spinifex Pharmaceuticals to be Acquired by Novartis

US$200 million upfront payment plus undisclosed clinical development and regulatory milestones Expands Novartis' neuroscience portfolio with novel...


03 Jun, 2014, 09:00 BST Spinifex Pharmaceuticals Appoints Neuroscience Expert Dr Ronald Marcus as Chief Medical Officer

Spinifex Pharmaceuticals, a pain drug development company, today announces that it has appointed Dr Ronald Marcus as Chief Medical Officer. Dr Marcus ...


27 May, 2014, 09:00 BST Spinifex Pharmaceuticals Strengthens Scientific Advisory Board (SAB) with Experts in Chronic Pain

Expanded SAB will oversee development of EMA401, Company's lead program for treating chronic pain Spinifex Pharmaceuticals, a pain drug development...


11 Apr, 2014, 00:01 BST Spinifex Pharmaceuticals Raises US$45m in Series C Financing

Syndicate includes Novo A/S and Canaan Partners alongside existing investors New funds to drive the development of Spinifex's lead candidate, EMA401, ...


05 Feb, 2014, 08:00 GMT Spinifex Pharmaceuticals' Phase 2 Results Published in The Lancet Show EMA401 to be Effective in Reducing Pain in Postherpetic Neuralgia

Phase 2 trial met its primary endpoint, reduced pain in postherpetic neuralgia (PHN) versus placebo Significant patient response to EMA401 treatment...


18 Oct, 2013, 09:00 BST Spinifex Pharmaceuticals' EMA401 Named One of the Top Ten Neuroscience Projects to Watch

Company to present at Elsevier Business Intelligence's 2013 Therapeutic Area Partnerships Spinifex Pharmaceuticals, an Australian pain drug...


27 Mar, 2013, 11:32 GMT Spinifex Receives $1.5m in R&D Tax Incentive for Research Activities Related to the Discovery of Treatments for Pain

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces it has received an approximately AUS$1.5 million R&D tax...


10 Dec, 2012, 09:00 GMT Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces that the first patients have been treated in its Phase 2 study ...


28 Aug, 2012, 07:00 BST Spinifex Announces Positive Phase 2 Results for EMA401 in Postherpetic Neuralgia

Trial Meets Primary Endpoint: Reduction in Pain Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive...


08 Dec, 2011, 10:13 GMT Spinifex Appoints Declan Doogan as Non-Executive Chairman

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces the appointment of Dr Declan Doogan as Non-Executive Chairman. ...


12 Sep, 2011, 09:00 BST New Data on EMA401 in Model of Diabetic Neuropathy Presented at 21st Annual NEURODIAB Meeting

EMA401 Shown to Improve Nerve and Neurovascular Function Spinifex Pharmaceuticals, an Australian pain drug development company, today announces the...


23 Aug, 2011, 09:00 BST Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round

Additional Funds to Broaden Phase 2 Program for New Pain Drug AU$6.25M (~US$6.5M) investment by GBS Venture Partners, Brandon Capital, Uniseed and...